# Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

> **NCT02366819** · PHASE4 · SUSPENDED · sponsor: **University of Chicago** · enrollment: 36 (estimated)

## Conditions studied

- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Stage IIB Gastric Cancer
- Stage IIIA Esophageal Adenocarcinoma
- Stage IIIA Gastric Cancer
- Stage IIIB Esophageal Adenocarcinoma
- Stage IIIB Gastric Cancer
- Stage IIIC Esophageal Adenocarcinoma
- Stage IIIC Gastric Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin Calcium
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Fluorouracil
- **PROCEDURE:** Conventional Surgery

## Key facts

- **NCT ID:** NCT02366819
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2014-12-11
- **Primary completion:** 2026-06-08
- **Final completion:** 2026-06-08
- **Target enrollment:** 36 (ESTIMATED)
- **Why stopped:** Pending data analysis
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366819, "Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02366819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*